Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News INmune Bio Inc INMB

Healthcare Biotechnology
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. It has two therapeutic platforms: a Dominant-Negative Tumor Necrosis Factor Platform (DN-TNF, XPro, XPro1595 or pegipanermin) and a Natural Killer (NK or INKmune) platform. The DN-TNF product platform utilizes dominant-negative technology to... see more

Recent & Breaking News (NDAQ:INMB)

INmune Bio, Inc. Announces Initiation of Clinical Program Targeting Soluble TNF to Determine if the Company's TNF Inhibitor (DN-TNF) Platform May Prevent Complications of Cytokine Storm Caused by COVID-19

GlobeNewswire April 20, 2020

INmune Bio, Inc. Reports Fourth Quarter and Full Year 2019 Results - Drug Pipeline Expands to Now Include Cancer, Alzheimer's Disease and NASH

GlobeNewswire March 11, 2020

INmune Bio, Inc. to Present at the 32nd Annual ROTH Conference on March 17

GlobeNewswire March 5, 2020

INmune Bio, Inc. Schedules Conference Call to Report 2019 Fourth Quarter and Full Year Financial Results

GlobeNewswire February 27, 2020

INmune Bio, Inc. Awarded $500,000 Grant for Development of Novel Treatment to Reprogram Innate Immune System in People Living with ALS

GlobeNewswire February 10, 2020

INmune Bio, Inc. Announces Data on its Lead Compound Which Highlights The Potential to Lower The Risk of Alzheimer's Disease in Obese Individuals

GlobeNewswire January 2, 2020

INmune Bio Announces Final Phase I Clinical Data for its Soluble TNF Inhibitor, INB03, Demonstrates Efficacy and Safety; INB03 is Advancing to Phase II Trials

GlobeNewswire December 17, 2019

INmune Bio, Inc. Announces First Alzheimer's Disease Patient Dosed in XPro1595 Study

GlobeNewswire December 2, 2019

INmune Bio Inc. to Discuss Potential New Alzheimer's Disease Treatments in CTAD Pre-Conference Webinar

GlobeNewswire November 26, 2019

INmune Bio, Inc. Strengthens Board of Directors with Appointment of Veteran Finance Executive Marcia Allen

GlobeNewswire November 19, 2019

INmune Bio, Inc. Reports Third Quarter 2019 Financial Results and Provides Shareholder Update

GlobeNewswire November 8, 2019

INmune Bio, Inc. Announces Potentially Strong Link Between Obesity and Alzheimer's Disease at the Society for Neuroscience 49th Annual Meeting

GlobeNewswire October 21, 2019

INmune Bio, Inc. Announces Presentation of Data Related to its Lead Compound XPro1595 at the Society for Neuroscience's Annual Meeting

GlobeNewswire October 17, 2019

INmune Bio Inc. to Present at Advances in Immuno-Oncology USA Congress and at World Immunotherapy Congress in October

GlobeNewswire October 8, 2019

CEO of INmune Bio Inc. Discusses Company Accomplishments at Nasdaq's MarketSite and Announces Presentation at World Immunotherapy Congress

GlobeNewswire September 24, 2019

INmune Bio to Present XPro1595 for Treating Neuroinflammation in Alzheimer's Disease at 2019 Alzheimer's Association International Conference (AAIC) Satellite Symposium

GlobeNewswire September 23, 2019

INmune Bio Invited to Speak on Company's Advancements in Cancer Treatments at the Targeting Innate Immunity Congress and MarketsandMarkets Next Gen Immuno-Oncology Congress

GlobeNewswire September 17, 2019

INmune Bio Inc. Announces USPTO Allowance of Key Patent Covering Its DN-TNFa Platform Technology for Treating Cancer

GlobeNewswire September 12, 2019

INmune Bio to Present at the H.C. Wainwright 21st Annual Healthcare Conference on Tuesday, September 10th at 2:10 p.m. ET

GlobeNewswire September 5, 2019

INmune Bio Reports Second Quarter 2019 Financial Results and Provides Shareholder Update

GlobeNewswire August 12, 2019